尼妥珠单抗联合奈达铂同期放化疗治疗局部晚期鼻咽癌临床研究  

Clinical study of nimotuzumab plus nadaplatin combined with concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma

作　　者：邵剑锋[1] 李曙平[1] 练英妮[1] 毛进星[1] 莫月媚[1] 

机构地区：[1]广东省肇庆市第一人民医院肿瘤科,526000

出　　处：《中国现代医药杂志》2014年第4期23-26,共4页Modern Medicine Journal of China

摘　　要：目的评价局部晚期鼻咽癌患者应用尼妥珠单抗联合奈达铂同期放化疗治疗方案的临床疗效和安全性。方法48例局部晚期鼻咽癌患者,随机分成观察组24例,对照组24例。两组患者均接受常规放射治疗。对照组于放射治疗的第1天起静脉滴注奈达铂30mg/m2,每周1次,连续7周。观察组在奈达铂基础上联合尼妥珠单抗100mg,每周1次,连续7周。结果治疗结束后3个月,观察组与对照组鼻咽肿瘤完全缓解率分别为87.5%和66.7%(P=0.168),颈部淋巴结完全缓解率分别为90.9%和67.5%(P=0.062),差异无统计学意义。中位随访26个月后,观察组与对照组的2年总生存率分别为87.5%和79.1%(P=0.675),2年无瘤生存率分别为75.0%和70.8%(P=0.738),差异无统计学意义。两组治疗毒性无明显差异。结论局部晚期鼻咽癌患者在奈达铂同步放化疗基础上,加用尼妥珠单抗可改善近期疗效,同时耐受性好,远期疗效仍需进一步观察。Objective To evaluate the efficacy and safety of nimotuzumab plus nadaplatin combined with concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Methods A total of 48 patients with advanced nasopharyngeal carcinoma were randomized into the experimental group（n=24） and the control group（n=24）. Radiotherapy was administered with the same way in both groups. The control group received nadaplatin 30mg/m^2 once a week for 7 weeks from the first day of radiotherapy. The experimental group was additionally given nimotuzumab 100mg once a week for 7 weeks on the basis of the control group. Results Three months after treatment,the complete response rate of the primary tumor in the experimental group and the control group were 87.5% and 66.7%（P=0.168）,the complete response rate of the cervical lymph node were 90.9% and 67.5%（P=0.062）. After a median follow-up of 26 months,the 2-year overall survival（OS） rate in the experimental group and the control group were 87.5% and 79.1%（P=0.675）,the 2-year disease-free survival（DFS） were 75.0% and 70.8%（P =0.738）. There was no significant difference between the two groups in the toxicity. Conclusion Nimotuzumab plus nadaplatin combined with concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma is effective and tolerable. Long-term outcome need to be further investigated.

关 键 词：鼻咽肿瘤 同期放化疗 尼妥珠单抗 奈达铂 

分 类 号：R739.63[医药卫生—肿瘤]